JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT

JPMorgan Chase & Co. trimmed its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 42.2% in the third quarter, HoldingsChannel.com reports. The fund owned 513,515 shares of the company’s stock after selling 374,501 shares during the quarter. JPMorgan Chase & Co.’s holdings in 4D Molecular Therapeutics were worth $4,462,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of 4D Molecular Therapeutics in the first quarter worth $39,000. Wexford Capital LP bought a new stake in 4D Molecular Therapeutics during the third quarter worth about $41,000. Quadrature Capital Ltd acquired a new stake in 4D Molecular Therapeutics during the second quarter worth about $42,000. Farther Finance Advisors LLC grew its stake in 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after buying an additional 2,674 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics in the 1st quarter valued at about $46,000. 99.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Chardan Capital restated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Royal Bank Of Canada lifted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Barclays began coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.25.

4D Molecular Therapeutics Trading Down 4.0%

FDMT stock opened at $9.48 on Friday. The firm has a 50-day moving average price of $9.05 and a 200-day moving average price of $9.27. 4D Molecular Therapeutics, Inc. has a 12 month low of $2.23 and a 12 month high of $12.34. The stock has a market capitalization of $483.95 million, a P/E ratio of -3.92 and a beta of 2.94.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.96. The company had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. As a group, equities analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.